Int Arch Allergy Immunol:间歇性过敏性鼻炎患者的血清CD48水平的提高

2020-10-27 AlexYang MedSci原创

在间歇性过敏性鼻炎(IAR)的发病机制中,炎症反应非常重要。CD48属于CD2家族,参与了肥大细胞刺激的cross-takl,并能够促进肥大细胞/嗜酸粒细胞效应单元的形成,且由嗜酸粒细胞表达。最近,有

在间歇性过敏性鼻炎(IAR)的发病机制中,炎症反应非常重要。CD48属于CD2家族,参与了肥大细胞刺激的cross-takl,并能够促进肥大细胞/嗜酸粒细胞效应单元的形成,且由嗜酸粒细胞表达。最近,有研究人员评估了IAR患者在花粉季节和非花粉季节血清中可溶性CD48的(sCD48)水平,并分析了与疾病严重程度和嗜酸性粒细胞相关参数的相关性。

研究包括了63名患者(女性:79%;平均年龄:30.58)。其中,45名患者在花粉季节进行评估,其他42名患者在非花粉季节进行评估。24名患者(女性:37.50%;平均年龄:27.90)在花粉季节和非花粉季节进行了两次评估。研究发现,花粉季节IAR组的sCD48血清水平、FeNO鼻腔和支气管评分和TNSS与非花粉季节相比明显升高。而ECP、eotaxin-1/CCL11的血清水平以及NLR和ELR在花粉季节和非花粉季节的差异不显著。另外,研究人员未发现sCD48与嗜酸性粒细胞相关参数之间相关性。

最后,研究人员指出,sCD48可能是IAR患者病情加重期的生物标志物,可以认为CD48参与了IAR的发病机制。

原始出处:

Olga Branicka , Edyta Jura-Szo?tys , Barbara Rogala et al. Elevated Serum Level of CD48 in Patients with Intermittent Allergic Rhinitis. Int Arch Allergy Immunol. Sep 2020

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1051026, encodeId=5c4710510269d, content=<a href='/topic/show?id=c0ae9405422' target=_blank style='color:#2F92EE;'>#过敏性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94054, encryptionId=c0ae9405422, topicName=过敏性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Tue Sep 14 10:27:57 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864285, encodeId=427b186428504, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat Jan 09 10:18:54 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047324, encodeId=dfa3204e3249b, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Aug 20 07:18:54 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955041, encodeId=b20019550413e, content=<a href='/topic/show?id=732f9e265d7' target=_blank style='color:#2F92EE;'>#间歇性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97265, encryptionId=732f9e265d7, topicName=间歇性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Jul 28 18:18:54 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329428, encodeId=318f1329428e3, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Oct 29 14:18:54 CST 2020, time=2020-10-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1051026, encodeId=5c4710510269d, content=<a href='/topic/show?id=c0ae9405422' target=_blank style='color:#2F92EE;'>#过敏性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94054, encryptionId=c0ae9405422, topicName=过敏性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Tue Sep 14 10:27:57 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864285, encodeId=427b186428504, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat Jan 09 10:18:54 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047324, encodeId=dfa3204e3249b, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Aug 20 07:18:54 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955041, encodeId=b20019550413e, content=<a href='/topic/show?id=732f9e265d7' target=_blank style='color:#2F92EE;'>#间歇性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97265, encryptionId=732f9e265d7, topicName=间歇性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Jul 28 18:18:54 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329428, encodeId=318f1329428e3, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Oct 29 14:18:54 CST 2020, time=2020-10-29, status=1, ipAttribution=)]
    2021-01-09 qidongfanjian
  3. [GetPortalCommentsPageByObjectIdResponse(id=1051026, encodeId=5c4710510269d, content=<a href='/topic/show?id=c0ae9405422' target=_blank style='color:#2F92EE;'>#过敏性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94054, encryptionId=c0ae9405422, topicName=过敏性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Tue Sep 14 10:27:57 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864285, encodeId=427b186428504, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat Jan 09 10:18:54 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047324, encodeId=dfa3204e3249b, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Aug 20 07:18:54 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955041, encodeId=b20019550413e, content=<a href='/topic/show?id=732f9e265d7' target=_blank style='color:#2F92EE;'>#间歇性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97265, encryptionId=732f9e265d7, topicName=间歇性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Jul 28 18:18:54 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329428, encodeId=318f1329428e3, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Oct 29 14:18:54 CST 2020, time=2020-10-29, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1051026, encodeId=5c4710510269d, content=<a href='/topic/show?id=c0ae9405422' target=_blank style='color:#2F92EE;'>#过敏性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94054, encryptionId=c0ae9405422, topicName=过敏性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Tue Sep 14 10:27:57 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864285, encodeId=427b186428504, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat Jan 09 10:18:54 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047324, encodeId=dfa3204e3249b, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Aug 20 07:18:54 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955041, encodeId=b20019550413e, content=<a href='/topic/show?id=732f9e265d7' target=_blank style='color:#2F92EE;'>#间歇性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97265, encryptionId=732f9e265d7, topicName=间歇性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Jul 28 18:18:54 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329428, encodeId=318f1329428e3, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Oct 29 14:18:54 CST 2020, time=2020-10-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1051026, encodeId=5c4710510269d, content=<a href='/topic/show?id=c0ae9405422' target=_blank style='color:#2F92EE;'>#过敏性鼻炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94054, encryptionId=c0ae9405422, topicName=过敏性鼻炎)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20211210/ede9c51184aa4f54ae6c1164cfb8eeac/967dbf3eff2943c7bf3ccfec3a776ab0.JPG, createdBy=a33789389, createdName=病毒猎手, createdTime=Tue Sep 14 10:27:57 CST 2021, time=2021-09-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1864285, encodeId=427b186428504, content=<a href='/topic/show?id=f930432538' target=_blank style='color:#2F92EE;'>#CD4#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4325, encryptionId=f930432538, topicName=CD4)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b09892, createdName=qidongfanjian, createdTime=Sat Jan 09 10:18:54 CST 2021, time=2021-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2047324, encodeId=dfa3204e3249b, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Fri Aug 20 07:18:54 CST 2021, time=2021-08-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955041, encodeId=b20019550413e, content=<a href='/topic/show?id=732f9e265d7' target=_blank style='color:#2F92EE;'>#间歇性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97265, encryptionId=732f9e265d7, topicName=间歇性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Wed Jul 28 18:18:54 CST 2021, time=2021-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329428, encodeId=318f1329428e3, content=<a href='/topic/show?id=bb96232801' target=_blank style='color:#2F92EE;'>#ALL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2328, encryptionId=bb96232801, topicName=ALL)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/C2EFD5CFB07FE291138AD4FD0C98E3DE/100, createdBy=e3d52500031, createdName=膀胱癌, createdTime=Thu Oct 29 14:18:54 CST 2020, time=2020-10-29, status=1, ipAttribution=)]
    2020-10-29 膀胱癌

相关资讯

Pharmaceutics:壳聚糖水凝胶掺杂PEG-PLA纳米颗粒来局部递送miRNA-146a和治疗变应性鼻炎

最近,有研究人员制备了一种递送miRNA-146的二元制剂,并通过调查其在过敏性鼻炎中的药效作用,评估了该核酸鼻腔递送系统。

PLoS One:便秘可能与过敏性鼻炎相关

过敏性鼻炎(AR)是一种让人感觉到很有负担的呼吸系统疾病,其病因和病理生理学仍有争议,很可能是多方面因素造成的。累积的证据表明,肠道失调能够导致AR。便秘可能导致肠道微生物菌群的改变,而便秘对AR的临

Environ Res:吸烟、环境烟草烟雾、室内粉刷和居住在新旧建筑中对哮喘、鼻炎和呼吸道症状影响情况的前瞻性研究

最近,有研究人员对北欧11506名成年人进行了为期10年的跟踪调查,探索了烟草烟雾、家庭环境和呼吸系统健康之间的关系。

Clin Otolaryngol:过敏性鼻炎舌下免疫治疗的回顾和元分析

过敏性鼻炎(AR)是一种常见的鼻黏膜炎症,影响着全球约20%的人口。目前的治疗方法包括鼻内抗组胺药、皮质类固醇、皮下和舌下免疫治疗(SLIT)。最近,有研究人员评估了SLIT在治疗草花粉诱导的成人AR

World Allergy Organ J:鼻对Der p的特异性IgE筛选测试不能预测非过敏性鼻炎患者鼻腔挑战试验结果

鼻特异性IgE(NsIgE)是鉴定局部过敏性鼻炎(LAR)中2型炎症的最常见标志物。然而,NsIgE在不同类型鼻炎中的比较、在热带国家中的频率以及预测鼻腔挑战试验(NCT)结果的诊断表现的相关研究有限

Exp Ther Med:白介素-33基因的单核苷酸多态性和单倍型与中国人群过敏性鼻炎的风险有关

过敏性鼻炎(AR)是一种常见的上呼吸道疾病,且归因于多种风险因素,如环境暴露和遗传易感性。临床上常见哮喘和AR并存,表明这些疾病之间存在共同的遗传风险因素和生物学机制。